Abivax S.A. American Depositary Receipt (ABVX)
NASDAQ (NMS) NASDAQ (NMS) Primary 
XSTU 
Alger Mid Cap Growth Fund Q4 2025 Portfolio Update
Class A shares of the Alger Mid Cap Growth Fund outperformed the Russell Midcap Growth Index during the fourth quarter of 2025. Cidara Therapeutics, Inc., Natera, Inc., and Abivax were among the top contributors to performance. Roblox Corp. Class A, e.l.f. Beauty, Inc., and Nebius Group were among the top detractors from performance.
Abivax CEO dismisses 'noise' around rumored Eli Lilly bid
Abivax Chief Executive Marc de Garidel dismissed as "noise" reports in the French press that pharmaceutical giant Eli Lilly may take over his company, and said market speculation about an ongoing review by French authorities was inconsistent with how French foreign-investment oversight works.
Abivax: Don't Just Buy The Rumor, Buy The Fundamentals
Abivax (ABVX) remains a Buy, driven by obefazimod's strong UC data and significant multi-billion dollar market potential. ABVX is a credible M&A target, with Eli Lilly and other pharma giants rumored as potential acquirers, but fundamentals—not acquisition hopes—should drive investment decisions. Key 2026 catalysts include Phase 3 UC maintenance topline data, potential NDA/MAA filings, and Phase 2B Crohn's disease results.
France has had no request for investment approval in biotech Abivax - official
France's finance ministry has received no request seeking investment approval in Abivax and has had no contact with Eli Lilly , a ministry official said on Monday, following media reports that the U.S. pharma giant was still interested in buying the French biotech firm.
Abivax Surges on Report Ely Lily is Preparing $17.5 Billion Bid
Stock in the French company has been rising steadily since late July, and climbed as much as 30% in early trading Monday.
Abivax shares soar 23% as media report reignites M&A chatter
Shares in Abivax soared 23%, exceeding 121 euros, on Monday after a media report said U.S. pharma giant Eli Lilly was still interested in buying the French biotech company.
Abivax: Here's Why Eli Lilly Could Want Its Oral Ulcerative Colitis Therapy
Abivax surged 1,470% YTD, driven by Obefazimod's clinical progress and takeover speculation, but I rate it Hold due to valuation risk. Obefazimod, a first-in-class oral therapy for ulcerative colitis, met key Phase 3 endpoints, with pivotal maintenance data expected mid-2026. ABVX boasts €589.7 million in cash, supporting operations through Q4 2027, despite high R&D-driven losses and a €15.3 million monthly cash burn.
Abivax: "Strong Buy" On Obefazimod New UC Data And Maintenance Results Coming Q2 2026
Abivax SA (ABVX) retains a "Strong Buy" rating, driven by positive phase 3 ABTECT induction data for obefazimod in moderate-to-severe ulcerative colitis. Upcoming catalysts include 44-week maintenance data from ABTECT trials in Q2 2026 and potential NDA/MAA filings in H2 2026, contingent on positive results. Obefazimod's oral dosing, favorable safety, and novel miR-124 mechanism position ABVX to penetrate 2nd/3rd-line UC therapy, move to 1st-line and expand into Crohn's disease.
French biotech Abivax's shares climb on Eli Lilly bid rumors
French biotech company Abivax's shares jumped by 20% on Wednesday on market rumours that U.S. pharma giant Eli Lilly might be interested in bidding for the business.
Abivax SA Sponsored ADR (ABVX) Upgraded to Buy: Here's What You Should Know
Abivax SA Sponsored ADR (ABVX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Are Medical Stocks Lagging Abivax SA Sponsored ADR (ABVX) This Year?
Here is how Abivax SA Sponsored ADR (ABVX) and Catalyst Pharmaceutical (CPRX) have performed compared to their sector so far this year.
Abivax: Betting Big On The Next Inflammatory Bowel Disease Blockbuster
ABIVAX Société Anonyme [NASDAQ: ABVX] is rated a Strong Buy with a $105 price target, driven by Obefazimod's best-in-class potential for ulcerative colitis (UC). ABVX's Obefazimod shows robust efficacy and differentiation in early Phase 3 trials, targeting a large, fast-growing inflammatory bowel disease market. Upcoming Phase 3 maintenance data in Q2 2026 is a major catalyst, with positive results likely to unlock significant upside for ABVX shares.
